Home Compare AZN.L vs NOVO-B.CO
Stock Comparison · Industry comparison · Drug Manufacturers - General

AstraZeneca vs Novo Nordisk A/S: Which Stock Looks Stronger in 2026?

Novo Nordisk A/S holds the cleaner structural position, with the lead spread across profitability and valuation. AstraZeneca still has the edge on stability, which keeps the comparison from looking entirely one-sided. In the market, AstraZeneca carries the stronger setup — intact trend against Novo Nordisk A/S's broken trend. That leaves a split case: the structural lead stays with Novo Nordisk A/S, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.

Updated 2026-05-17

This is not just a one-metric split: both profitability and valuation materially support the lead. Novo Nordisk A/S leads by 33 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AZN.L and NOVO-B.CO share the same industry classification.

For a similarity-based comparison, see how AstraZeneca and Novo Nordisk A/S each position within their functional peer groups in AssetNext.

Peer-Relative Score
AZN.L
AstraZeneca PLC
44
Peer-Score
Signal qualitylow
Peer basis: STOXX 600
vs
NOVO-B.CO
Novo Nordisk A/S
77
Peer-Score
Signal qualitylow
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: AZN.L vs NOVO-B.CO Profitability 35 91 Stability 51 34 Valuation 47 88 Growth 44 80 AZN.L NOVO-B.CO
Gap Ranking
#1 Profitability +56
#2 Valuation +41
#3 Growth +36
#4 Stability +17
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AZN.L and NOVO-B.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AZN.LNOVO-B.CO Relative valuation Structural strength

Novo Nordisk A/S looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, Novo Nordisk A/S ranks near the top of the group; AstraZeneca PLC sits in the weaker half.
Valuation
On valuation, the same pattern holds: both are strong, but Novo Nordisk A/S still leads clearly.
Profitability — Dominant Gap
AZN.L
35
NOVO-B.CO
91
Gap+56in favour of NOVO-B.CO

The profitability lead is mainly driven by a 33-point operating margin advantage.

What keeps the gap from being one-sided

AstraZeneca PLC still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

The lead is built on both profitability and valuation — though stability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the AZN.L vs NOVO-B.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-valuation comparisons

Explore how AZN.L and NOVO-B.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.